JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2026, 75(1):E12-E18 | DOI: 10.36290/csf.2026.010

Drug unavailability increases off-label prescribing in the pediatric population in Slovakia

Michala Hrončová1, 2, Simona Valášková2, Andrea Gažová2
1 Poliklinka Tehelná, Lekáreň Ferox, Bratislava
2 Ústav farmakológie a klinickej farmakológie, Lekárska fakulta Univerzity Komenského, Bratislava

Drug shortages may lead to interruption of ongoing treatment, delays in therapy initiation, or the need to modify therapeutic regimens. This represents a current and persistent problem that requires systematic and long-term solutions, as it may be a significant contributing factor to off-label prescribing. Between 2018 and 2020, the occurrence of drug shortages increased up to twentyfold, accompanied by a growing demand for essential medicines. The aim of this study was to analyse the occurrence of off-label prescribing in the paediatric population in a community pharmacy and to assess a possible association between the unavailability of a selected medicine and an increase in off-label use of a therapeutic alternative. A retrospective analysis was conducted using data obtained from pharmacy software and the national eHealth system for the period 2021-2024. A total of 6,366 paediatric patients were included in the analysis, with off-label prescribing identified in 705 cases (11.07%). Off-label use most frequently involved antibiotics for systemic use and ophthalmological medicines, with the highest proportion of off-label prescribing within an ATC group observed for ophthalmological drugs. In evaluating the relationship between the unavailability of Pamycon and increased off-label prescribing of Uniflox 0.3% eye drops, no statistically significant association was demonstrated (p > 0.05). Off-label prescribing is a common component of paediatric pharmacotherapy and is influenced by multiple factors beyond medicine availability alone. Pharmacists play an important role in ensuring safe treatment by identifying potential risks, educating parents or caregivers, and supporting the rational use of medicines. Strengthening collaboration among healthcare professionals and consistent pharmacovigilance are essential for improving the safety of off-label treatment in children.

Keywords: off-label, drug shortages, paediatric population, prescriptions, age group.

Accepted: February 19, 2026; Published: March 13, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrončová M, Valášková S, Gažová A. Drug unavailability increases off-label prescribing in the pediatric population in Slovakia. Čes. slov. farm. 2026;75(1):E12-18. doi: 10.36290/csf.2026.010.
Download citation

References

  1. Heads of Medicines Agencies (HMA). Availability of Medicines for Human Use [Internet]. London: HMA; [cited 2025 Oct 15]. Available from: https://www.hma.eu/human-medicines/availability-of-medicines.html
  2. EURÓPSKY PARLAMENT A RADA EURÓPSKEJ ÚNIE. Nariadenie (ES) č. 1901/2006 Európskeho parlamentu a Rady z 12. decembra 2006 o liekoch na pediatrické použitie a o zmene a doplnení nariadenia (EHS) č. 1768/92, smernice 2001/20/ES, smernice 2001/83/ES a nariadenia (ES) č. 726/2004. Úradný vestník Európskej únie. 2006, L 378, s. 1-19.
  3. EUROPEAN MEDICINES AGENCY. Paediatric Committee (PDCO) - role and responsibilities [online]. Amsterdam: EMA, 2021 [cit. 2026-02-08]. Dostupné na: https://www.ema.europa.eu/en/committees/paediatric-committee-pdco
  4. EUROPEAN MEDICINES AGENCY. Paediatric investigation plans (PIPs) - guidance and procedural information [online]. Amsterdam: EMA, 2025 [cit. 2026-02-08]. Dostupné na: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/paediatric-medicines-research-and-development/paediatric-investigation-plans
  5. EUROPEAN MEDICINES AGENCY. Paediatric-use marketing authorisations (PUMA) [online]. Amsterdam: EMA, 2025 [cit. 2026-02-08]. Dostupné na: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/paediatric-medicines-marketing-authorisation/paediatric-use-marketing-authorisations
  6. European Parliament. Report on the shortage of medicines - how to address an emerging problem (2020/2071(INI)) [Internet]. Brussels: European Parliament; 2020 [cited 2025 Oct 15]. Available from: https://www.europarl.europa.eu/doceo/document/A-9-2020-0142_EN.html
  7. European Medicines Agency. First version of the Union list of critical medicines agreed to help avoid potential shortages in the EU [Internet]. Amsterdam: EMA; 2023 [cited 2025 Oct 15]. Available from: https://www.ema.europa.eu/en/news/first-version-union-list-critical-medicines-agreed-help-avoid-potential
  8. Slovenská republika. Zákon č. 363/2011 Z. z. o rozsahu a podmienkach úhrady liekov, zdravotníckych pomôcok a dietetických potravín na základe verejného zdravotného poistenia [Internet]. Bratislava: Zbierka zákonov Slovenskej republiky; 2011 [cited 2025 Oct 15]. Available from: https://static.slov-lex.sk/static/SK/ZZ/2011/363/20170101.html
  9. Slovenská republika. Zákon č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach a o zmene a doplnení niektorých zákonov [Internet]. Bratislava: Zbierka zákonov Slovenskej republiky; 2011 [cited 2025 Oct 15]. Available from: https://www.slov-lex.sk/pravne-predpisy/SK/ZZ/2011/362/
  10. Breitkreutz J. European perspectives on pediatric formulations. Clin Ther. 2008 Nov;30(11):2146-54. doi: 10.1016/j.clinthera.2008.11.016. PMID: 19108802. Go to original source... Go to PubMed...
  11. Yuan X, Gao J, Yang L, Tan Y, Bajinka O. Off-label and unapproved pediatric drug utilization: A meta-analysis.Experimental and Therapeutic Medicine. 2024;28(5):412. doi:10.3892/etm.2024.12701. Go to original source... Go to PubMed...
  12. Matalová P, Belfínová L, Vrbicová K, Fürstová J, Wawruch M. Zhodnocení incidence unlicensed a off-label předpisu léčiv u dětí. Klinická farmakologie a farmacie. 2024;38(2):52-54. doi: 10.36290/far.2024.008. Go to original source...
  13. SCHWEIGERTOVÁ, J., et al. Off-label and unlicensed use of medicinal products in hospitalised neonates and infants in Slovakia: a cross-sectional study. Acta Paediatrica. 2016, roč. 105, č. 6, s. e210-e215. DOI: 10.1111/ped.12771. Go to original source... Go to PubMed...
  14. Smith J., Müller P., García L., Novak T. Off-label prescribing in paediatric patients. Acta Paediatrica, 2021, roč. 110, č. 11, s. 3255-3263. DOI: 10.1111/ped.12771. Go to original source... Go to PubMed...
  15. Petkova V, Georgieva D, Dimitrov M, Nikolova I. Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022. Pharmaceutics. 2023 Nov 21;15(12):2652. doi: 10.3390/pharmaceutics15122652. PMID: 38139994; PMCID: PMC107 Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.